Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
October
26, 2007 (October 23, 2007)
Date
of
Report (Date of earliest event reported)
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
(Exact
name of registrant as specified in its charter)
Florida
|
333-86347
|
65-1130026
|
(State
or other jurisdiction of
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
incorporation)
|
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
710075
|
(Address
of principal executive offices)
|
(0086)
535-7282997
Registrant’s
telephone number, including area code
Genesis
Technology Group, Inc.
7900
Glades Road, Suite 420, Boca Raton, Florida 33434
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.03 Amendments to
Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
October 23, 2007, Genesis Technology Group, Inc. (the “Company”) received
confirmation from the Department of State of Florida (“Department”) that the
amendment filed by the Company to its Articles of Incorporation to change its
name, change its principal office and mailing address, and increase its
authorized number of shares of common stock (“Amendment”) was duly filed with
the Department on October 16, 2007. The effective date of the Amendment was
October 12, 2007. A copy of the Amendment is included as Exhibit 3.1 to this
Current Report on Form 8-K.
Pursuant
to the Amendment:
The
Company’s name was changed to “Genesis Pharmaceuticals Enterprises, Inc.”
The
Company’s principal office and mailing address was changed from 7900 Glades
Road, Suite 420, Boca Raton, Florida 33434 to Middle Section, Longmao Street,
Area A, Laiyang Waixiangxing Industrial Park, Laiyang City, Yantai, Shandong
Province, People’s Republic of China 710075.
The
Company’s authorized number of shares of common stock was increased from
200,000,000 to 600,000,000 shares.
Item
9.01 Financial Statements
and Exhibits.
Exhibit
|
Description
|
3.1
|
Articles
of Amendment filed with the Department of State of Florida on October
16,
2007 with an effective date of October 12, 2007.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
|
|
(Registrant)
|
|
|
Date:
October 26, 2007
|
/s/
Cao Wubo
|
|
Name:
Cao Wubo
|
|
Title:
Chief Executive Officer
|